@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases urinary tract infections caused by e coli p mirabilis klebsiella skin and skin structure infections caused by staphylococci streptococci pharyngitis and or tonsillitis caused by streptococcus pyogenes note only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever cefadroxil is generally effective in the eradication of streptococci from the oropharynx however data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available note to reduce the development of drug resistant bacteria and maintain the effectiveness of cefadroxil capsules usp and other antibacterial drugs cefadroxil capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "XgW/QFmGXSzFplltl+KCzNcXDy4KeybjvH6oSnS21JyQ6fKlND/FDGyZXQfyve7j8SRIICx1lLzyuyUngQGAvZTkuIqftXpobbZbcAoRnEBLqcEmn4BTv9Sg35EPEsxwYIW8KknyM7NPdNlV4UVtwLUxm44sZl0kRc4RvsA3i5g=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-06-28T09:00:11.653+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}